Guardant Health

Guardant Health's mission is to transform cancer care by unlocking critical insights from a simple blood draw, shifting the paradigm from reactive to proactive, data-driven management. The company has achieved significant clinical adoption with over 500,000 commercial tests performed by more than 12,000 oncologists and secured FDA approval for its colorectal cancer screening test, Guardant Shield. Its strategy is built on a three-pillar business model spanning Clinical diagnostics, Biopharma solutions, and a high-growth Screening franchise, all powered by its proprietary liquid biopsy and multi-omic platform, Guardant Infinity.

Proprietary liquid biopsy platform analyzing circulating tumor DNA (ctDNA) for genomic and epigenomic profiling, enabling cancer detection, treatment selection, and monitoring from a simple blood draw.

Guardant faces competition from Foundation Medicine/Roche in advanced cancer profiling, Exact Sciences in CRC screening, and Grail (Illumina) in multi-cancer early detection. Its differentiation lies in its commercial scale in liquid biopsy, its multi-omic Infinity platform, and its integrated business model across clinical, biopharma, and screening segments.